MindMed is a psychedelic company addressing unmet medical need GAD (Generalized Anxiety Disorder) with lead drug MM-120. The companies website is here MindMed. Some quick facts regarding MindMed.
- 540 Million Market Cap
- 80M Shares outstanding
- 295 Million cash
- MM-120 Breakthrough Therapy Designation
- MM-120 Patent to 2041
- MM-120 in Phase 3 for GAD
The company has successfully completed a phase 2b for GAD, and received Breakthrough Therapy Designation for MM-120 afterwards. The company is now in phase 3 for GAD. They will be using the HAM-A assessment at 12 weeks, after a single dose of MM-120. You can find the company medical Presntations here. The goal of MindMed is to have two phase 3 clinical trials and a 40 week long-term extension study all completed by the end of 2026. Their past and current clinical trails MM-120 Clinical Trials. Thank you for reading.
No comments:
Post a Comment